167 related articles for article (PubMed ID: 29328641)
1. Correlation of local and systemic expression of survivin with histopathological parameters of cutaneous melanoma.
Jović M; Cerović S; Zolotarevska L; Gačević M; Stanojević I; Miller K; Đukić M; Saso L; Jauković L; Vojvodić D
Vojnosanit Pregl; 2016 Nov; 73(11):1022-9. PubMed ID: 29328641
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
3. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
[TBL] [Abstract][Full Text] [Related]
4. Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Gacević M; Jović M; Zolotarevski L; Stanojević I; Novaković M; Miller K; Šuljagić V; Mijušković Ž; Vojvodić D
Vojnosanit Pregl; 2016 May; 73(5):449-57. PubMed ID: 27430109
[TBL] [Abstract][Full Text] [Related]
5. Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma.
Tas F; Erturk K
Int J Dermatol; 2017 Feb; 56(2):166-170. PubMed ID: 27778319
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with localized primary cutaneous melanoma.
Mervic L
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(2):27-31. PubMed ID: 23000937
[TBL] [Abstract][Full Text] [Related]
7. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
8. Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases.
Hung T; Morin J; Munday WR; Mackenzie IR; Lugassy C; Barnhill RL
Am J Dermatopathol; 2013 Aug; 35(6):650-4. PubMed ID: 23392133
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
10. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
Takeuchi H; Morton DL; Elashoff D; Hoon DS
Int J Cancer; 2005 Dec; 117(6):1032-8. PubMed ID: 15986442
[TBL] [Abstract][Full Text] [Related]
12. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Becker JC; Andersen MH; Hofmeister-Müller V; Wobser M; Frey L; Sandig C; Walter S; Singh-Jasuja H; Kämpgen E; Opitz A; Zapatka M; Bröcker EB; Thor Straten P; Schrama D; Ugurel S
Cancer Immunol Immunother; 2012 Nov; 61(11):2091-103. PubMed ID: 22565484
[TBL] [Abstract][Full Text] [Related]
13. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
[TBL] [Abstract][Full Text] [Related]
14. Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma.
Storr SJ; Safuan S; Mitra A; Elliott F; Walker C; Vasko MJ; Ho B; Cook M; Mohammed RA; Patel PM; Ellis IO; Newton-Bishop JA; Martin SG
Mod Pathol; 2012 Apr; 25(4):493-504. PubMed ID: 22080065
[TBL] [Abstract][Full Text] [Related]
15. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
19. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
20. Correlation of nuclear morphometry of primary melanoma of the skin with clinicopathological parameters and expression of tumor suppressor proteins (p53 and p16(INK4a)) and bcl-2 oncoprotein.
Mijovic Z; Kostov M; Mihailovic D; Zivkovic N; Stojanovic M; Zdravkovic M
J BUON; 2013; 18(2):471-6. PubMed ID: 23818364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
